Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer

NCT04693234 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04693234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04693234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
February 15, 2021
Completion date
August 31, 2023
Enrollment
178 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer